ES2173626T3 - Metodos y composiciones para tratar la artritis reumatoide. - Google Patents
Metodos y composiciones para tratar la artritis reumatoide.Info
- Publication number
- ES2173626T3 ES2173626T3 ES98948455T ES98948455T ES2173626T3 ES 2173626 T3 ES2173626 T3 ES 2173626T3 ES 98948455 T ES98948455 T ES 98948455T ES 98948455 T ES98948455 T ES 98948455T ES 2173626 T3 ES2173626 T3 ES 2173626T3
- Authority
- ES
- Spain
- Prior art keywords
- carbonyl
- methylprolyl
- residue
- tert
- isoleucyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010003246 arthritis Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- -1 3-tert-butylalanyl Chemical group 0.000 abstract 30
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 229950003188 isovaleryl diethylamide Drugs 0.000 abstract 3
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 3
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 abstract 2
- 125000001998 leucyl group Chemical group 0.000 abstract 2
- 125000002114 valyl group Chemical group 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 125000001980 alanyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000000405 phenylalanyl group Chemical group 0.000 abstract 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000005454 tryptophanyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Uso, para la fabricación de un medicamento para el tratamiento de la artritis reumatoide en un mamífero, de un compuesto de Fórmula I: R 1 R 2 N-CHX-CO-A-B-D-(E)s-(F)t-(G)u-K (I) en la que: R 1 es alquilo, cicloalquilo, alquilsulfonilo, fluoroalquilo o aminosulfonilo; R 2 es hidrógeno, alquilo,fluoroalquilo o cicloalquilo; R 1 -N-R 2 juntos pueden ser un residuo de pirrolidino o piperidino; A es un residuo de valilo, isoleucilo, leucilo, alo-isoleucilo, 2,2-dimetilglicilo, 2-ciclopropilglicilo, 2-ciclopentilglicilo, 3-terc-butilalanilo, 2-terc-butilglicilo, 3-ciclohexilalanilo, 2-etilglicilo, 2-ciclohexilglicilo, norleucilo o norvalilo; B es un residuo de N-alquil-valilo, -norvalilo, -leucilo, -isoleucilo, -2-terc-butilglicilo, -3-terc-butilalanilo, -2-etilglicilo, -2-ciclopropilglicilo, -2-ciclopentilglicilo, -norleucilo o -2-ciclohexilglicilo; D es un residuo de prolilo, homoprolilo, hidroxiprolilo, 3,4-deshidroprolilo, 4uoroprolilo, 3-metilprolilo, 4-metilprolilo, 5-metilprolilo, azetidin-2-carbonilo, 3,3-dimetilprolilo, 4,4-di fluoroprolilo, oxazolidin4-carbonilo o tiazolidin-4-carbonilo; E es un residuo de prolilo, homoprolilo, hidroxiprolilo, 3,4-deshidroprolilo, 4uoroprolilo, 3-metilprolilo, 4-metilprolilo, 5-metilprolilo, azetidin-2-carbonilo, 3,3-dimetilprolilo, 4,4-di uoroprolilo, oxazolidin4-carbonilo o tiazolidin-4-carbonilo; F y G se seleccionan independientemente del grupo que consiste en residuos de prolilo, homoprolilo, hidroxiprolilo, tiazolidinil-4-carbonilo, 1-aminopentil-1-carbonilo, valilo, 2-terc-butilglicilo, isoleucilo, leucilo, 3-ciclohexilalanilo, fenilalanilo, N-metilfenilalanilo, tetrahidroisoquinolil-2-histidilo, 1-aminoindil-1-carbonilo, 3-piridilalanilo, 2-ciclohexilglicilo, norleucilo, norvalilo, neopentilglicilo, triptofanilo, glicilo, 2,2-dimetilglicilo, alanilo, -alanilo y 3-naftilalanilo; X eshidrógeno, alquilo, cicloalquilo, -CH2-ciclohexilo o arilalquilo; s, t y u son independientemente 0 ó 1;y K es hidroxi, alcoxi, fenoxi, benciloxi o unresto amino sustituido o no sustituido; y las sales del mismo con ácidos fisiológicamente tolerados.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/944,479 US6015790A (en) | 1997-10-06 | 1997-10-06 | Methods and compositions for treating rheumatoid arthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2173626T3 true ES2173626T3 (es) | 2002-10-16 |
Family
ID=25481479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES98948455T Expired - Lifetime ES2173626T3 (es) | 1997-10-06 | 1998-09-24 | Metodos y composiciones para tratar la artritis reumatoide. |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US6015790A (es) |
| EP (1) | EP1021200B1 (es) |
| JP (1) | JP2001518515A (es) |
| KR (1) | KR20010081900A (es) |
| CN (1) | CN1278734A (es) |
| AR (1) | AR017298A1 (es) |
| AT (1) | ATE212855T1 (es) |
| AU (2) | AU748465B2 (es) |
| BG (1) | BG104292A (es) |
| BR (1) | BR9812875A (es) |
| CA (1) | CA2305688A1 (es) |
| DE (1) | DE69803792D1 (es) |
| DK (1) | DK1021200T3 (es) |
| ES (1) | ES2173626T3 (es) |
| HR (1) | HRP20000265A2 (es) |
| HU (1) | HUP0101715A3 (es) |
| IL (1) | IL135167A0 (es) |
| NO (1) | NO20001758L (es) |
| PL (1) | PL339731A1 (es) |
| PT (1) | PT1021200E (es) |
| SK (1) | SK4272000A3 (es) |
| TR (1) | TR200000903T2 (es) |
| WO (2) | WO1999017792A1 (es) |
| ZA (1) | ZA989036B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010009901A1 (en) * | 1996-12-11 | 2001-07-26 | Basf Aktiengesellschaft Germany | Antineoplastic peptides |
| KR100261114B1 (ko) * | 1998-01-24 | 2000-07-01 | 박종헌 | 히스톤을 함유하는 류마티스 관절염 치료제 조성물 |
| EP1214087A1 (en) * | 1999-09-14 | 2002-06-19 | Pfizer Products Inc. | Combination treatment with il-1ra and compounds that inhibit il-1 processing and release |
| AU1730701A (en) * | 1999-12-07 | 2001-06-18 | Santen Pharmaceutical Co. Ltd. | Rheumatism remedy containing tetrapeptide derivative as active ingredient |
| KR100468254B1 (ko) * | 1999-12-24 | 2005-01-27 | 에프. 호프만-라 로슈 아게 | 카텝신 ｋ 억제제로서의 니트릴 유도체 |
| KR20090096716A (ko) * | 2007-01-09 | 2009-09-14 | 바이엘 쉐링 파마 악티엔게젤샤프트 | 아지리딘의 플루오르화에 의한 방사성표지 |
| WO2010147547A1 (en) * | 2009-06-18 | 2010-12-23 | Neobiotics Ab | Novel peptide derivatives for treatment, prevention or alleviation of a condition associated with bone loss or low bone density or to inhibit osteoclast differentiation and stimulation |
| WO2014109414A1 (ja) * | 2013-01-11 | 2014-07-17 | 富士フイルム株式会社 | 含窒素複素環化合物またはその塩 |
| KR102372512B1 (ko) * | 2017-11-20 | 2022-03-10 | 가톨릭대학교 산학협력단 | 폴리감마글루탐산 및 메토트렉세이트를 유효성분으로 포함하는 관절염 예방 또는 치료용 조성물 |
| CN115281149A (zh) * | 2021-05-12 | 2022-11-04 | 四川大学华西医院 | 一种临床前类风湿关节炎(Pre-RA)小鼠模型 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816444A (en) * | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
| US4879278A (en) * | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
| SG87056A1 (en) * | 1991-08-09 | 2002-03-19 | Teikoku Hormone Mfg Co Ltd | Novel tetrapeptide derivative |
| US5831002A (en) * | 1992-05-20 | 1998-11-03 | Basf Aktiengesellschaft | Antitumor peptides |
| AU679479B2 (en) * | 1992-12-16 | 1997-07-03 | Basf Aktiengesellschaft | Dolostatin analog |
| US5504191A (en) * | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
| US5530097A (en) * | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
| US5583153A (en) * | 1994-10-06 | 1996-12-10 | Regents Of The University Of California | Use of taxol in the treatment of rheumatoid arthritis |
-
1997
- 1997-10-06 US US08/944,479 patent/US6015790A/en not_active Expired - Fee Related
-
1998
- 1998-09-24 PL PL98339731A patent/PL339731A1/xx not_active Application Discontinuation
- 1998-09-24 KR KR1020007003706A patent/KR20010081900A/ko not_active Withdrawn
- 1998-09-24 PT PT98948455T patent/PT1021200E/pt unknown
- 1998-09-24 TR TR2000/00903T patent/TR200000903T2/xx unknown
- 1998-09-24 JP JP2000514663A patent/JP2001518515A/ja not_active Withdrawn
- 1998-09-24 CN CN98811034A patent/CN1278734A/zh active Pending
- 1998-09-24 IL IL13516798A patent/IL135167A0/xx unknown
- 1998-09-24 AT AT98948455T patent/ATE212855T1/de not_active IP Right Cessation
- 1998-09-24 AU AU95024/98A patent/AU748465B2/en not_active Ceased
- 1998-09-24 HU HU0101715A patent/HUP0101715A3/hu unknown
- 1998-09-24 BR BR9812875-2A patent/BR9812875A/pt not_active IP Right Cessation
- 1998-09-24 ES ES98948455T patent/ES2173626T3/es not_active Expired - Lifetime
- 1998-09-24 SK SK427-2000A patent/SK4272000A3/sk unknown
- 1998-09-24 DE DE69803792T patent/DE69803792D1/de not_active Expired - Fee Related
- 1998-09-24 WO PCT/US1998/019841 patent/WO1999017792A1/en not_active Ceased
- 1998-09-24 EP EP98948455A patent/EP1021200B1/en not_active Expired - Lifetime
- 1998-09-24 DK DK98948455T patent/DK1021200T3/da active
- 1998-09-24 HR HR20000265A patent/HRP20000265A2/hr not_active Application Discontinuation
- 1998-09-24 CA CA002305688A patent/CA2305688A1/en not_active Abandoned
- 1998-09-30 AU AU95926/98A patent/AU9592698A/en not_active Withdrawn
- 1998-09-30 WO PCT/US1998/020465 patent/WO1999017709A2/en not_active Ceased
- 1998-10-05 ZA ZA9809036A patent/ZA989036B/xx unknown
- 1998-10-06 AR ARP980104972A patent/AR017298A1/es not_active Application Discontinuation
-
2000
- 2000-04-03 BG BG104292A patent/BG104292A/xx unknown
- 2000-04-05 NO NO20001758A patent/NO20001758L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR017298A1 (es) | 2001-09-05 |
| WO1999017709A2 (en) | 1999-04-15 |
| KR20010081900A (ko) | 2001-08-29 |
| US6015790A (en) | 2000-01-18 |
| AU748465B2 (en) | 2002-06-06 |
| AU9592698A (en) | 1999-04-27 |
| WO1999017792A1 (en) | 1999-04-15 |
| HRP20000265A2 (en) | 2000-12-31 |
| HUP0101715A3 (en) | 2001-12-28 |
| BR9812875A (pt) | 2000-08-08 |
| EP1021200B1 (en) | 2002-02-06 |
| ATE212855T1 (de) | 2002-02-15 |
| BG104292A (en) | 2000-12-29 |
| NO20001758L (no) | 2000-06-05 |
| NO20001758D0 (no) | 2000-04-05 |
| TR200000903T2 (tr) | 2001-07-23 |
| EP1021200A1 (en) | 2000-07-26 |
| DE69803792D1 (de) | 2002-03-21 |
| DK1021200T3 (da) | 2002-05-27 |
| ZA989036B (en) | 2000-04-05 |
| IL135167A0 (en) | 2001-05-20 |
| HUP0101715A2 (hu) | 2001-11-28 |
| AU9502498A (en) | 1999-04-27 |
| CA2305688A1 (en) | 1999-04-15 |
| CN1278734A (zh) | 2001-01-03 |
| PT1021200E (pt) | 2002-07-31 |
| JP2001518515A (ja) | 2001-10-16 |
| SK4272000A3 (en) | 2001-02-12 |
| PL339731A1 (en) | 2001-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR003136A1 (es) | Peptidos de dolastatin, procedimiento para prepararlos, las composiciones farmaceuticas que los contienen y el uso de los mismos para preparar dichas composiciones farmaceuticas. | |
| AR002043A1 (es) | Utilizacion de agonistas de alfa (1l) para el tratamiento de la incontinencia urinaria. | |
| BR9406779A (pt) | Complexos de inclusão de multicomponentes altamente solúveis contendo uma droga de tipo básico um ácido e uma ciclodextrina | |
| DE69531457D1 (en) | Sulfonamide | |
| AR023529A1 (es) | Una composicion champu acondicionadora del cabello y un metodo para acondicionar el cabello | |
| AR018501A1 (es) | Derivados de la dolastatina 15 | |
| BR9609393A (pt) | Composição injetável de colágeno; segmentos de fibra de colágeno reconstituìdos. | |
| IS2833B (is) | 1,5 Bensóþíósepín og notkun þeirra gegn fitublæði | |
| HUP0301842A2 (hu) | Laktám vegyület, a vegyületet tartalmazó gyógyszerkészítmény és alkalmazása gyógyszerkészítmény elżállítására | |
| BG104679A (en) | The use of fumaric acid derivatives in transplant medicine | |
| TR200102648T2 (tr) | Büyümeyi destekleyen bileşimler | |
| NO20021281D0 (no) | Vaskul¶r beleggingssammensetning | |
| ES2114068T3 (es) | Hidroxialquilamidas de acidos dicarboxilicos y su uso en composiciones cosmeticas. | |
| IL151371A0 (en) | Modified porcine factor viii and pharmaceutical compositions containing the same | |
| DK1351722T3 (da) | Knogleimplantat | |
| CO5540368A2 (es) | Composicion de liberacion sostenida y proceso para producirla | |
| BR0008738A (pt) | Moduladores de agregação de peptìdeobeta-amilóide compreendendo d-aminoácidos | |
| AR040441A1 (es) | Compuesto de tiol, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento, procedimiento para prepararlo y compuesto intermediario de utilidad en dicho procedimiento | |
| ES2150907T3 (es) | Derivados de aminoacidos. | |
| AR017298A1 (es) | USO DE UN COMPUESTO DERIVADO DE DEPSIPEPTIDO DOLASTINA-15 (Dov-Val-NMeVal-Pro-Pro-Hiva-Dpy) PARA LA PREPARACION DE UNA COMPOSICION FARMACEUTICA PARA ELTRATAMIENTO DE ARTRITIS REUMATOIDEA EN UN MAMIFERO | |
| ES8105865A1 (es) | Un procedimiento para la determinacion cuantitativa de enzi-mas proteoliticas | |
| AR031126A1 (es) | Acidos amino(oxo)aceticos inhibidores de la proteina tirosina fosfatasa | |
| BRPI0414812A (pt) | método de inibir a expressão de genes resistentes a múltiplos medicamentos e de inibir a produção de proteìnas resultantes da expressão de tais gene, melhorando assim a efetividade dos agentes quimioterápicos para tratar cánceres | |
| ATE291587T1 (de) | Somatostatin analoge und deren verwendung zur behandlung von krebs | |
| TR200100182T2 (tr) | Antitrombotik etkili ikame edilmiş fenilamidinler |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 1021200 Country of ref document: ES |